Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
My Lists

Rigel Pharmaceuticals  (Stock symbol: RIGL )

1180 Veterans Blvd.
South San Francisco, CA 94080
Website Company Summary Management Team

Outside board: (May no longer be on the board) Keith Katkin (InterMune) Bradford S. Goodwin (Novacea Former CEO) Peter S. Ringrose (Biotechnology & Biological Sciences Research Council Chairman) Gary A. Lyons (Nuerocrine Biosciences President/CEO) Walter H. Moos (MitoKor CEO) Stephen A. Sherwin (Cell Genesys Former CEO)
Former outside board: Jean Deleage (Alta Partners Managing Director) Alan D. Frazier (Frazier & Co);  Dennis Henner (MPM Capital) Hollings C. Renton (Onyx Pharmaceuticals CEO) Nicholas J. Simon (MPM Capital) Tom Volpe (Prudential Volpe)

Business description: Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs. The company's business model is to develop a portfolio of drug candidates and to take these through phase II clinical trials, after which Rigel intends to seek commercialization partners for completion of clinical evaluation, regulatory approval and marketing. Rigel has identified three areas for its lead product research programs: mast cell activation to treat immunologic diseases such as asthma/allergy and autoimmune disorders, an antiviral agent to treat hepatitis C, and ubiquitin ligases, a new class of cancer drug target.
Partners include: AstraZeneca Cell GenesysJohnsonAndJohnsonMerckPfizer;  Daiichi Pharmaceuticals;  Novartis Pharma;  Serono

Rounds: 4
Capital raised: 45.7M
Ownership: Public  
Stock Symbol: RIGL
VCs include: Alta PartnersJF SheaAndCo.

Last Tweets


Last Mentions

Record updated: Aug 2020
Sector: Biotech
Year Founded: 1996
Headcount: 201-300 as of Jul 2021
Rounds: 4
Capital Raised: 45.7M
Ownership: Public  
Stock Symbol: RIGL